Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection

J Am Coll Cardiol. 2012 May 29;59(22):1921-7. doi: 10.1016/j.jacc.2011.09.086.

Abstract

Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Guanosine Monophosphate / metabolism*
  • Heart Diseases / drug therapy*
  • Heart Diseases / metabolism
  • Heart Diseases / pathology
  • Humans
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Signal Transduction

Substances

  • Phosphodiesterase 5 Inhibitors
  • Guanosine Monophosphate